Subscribe to our News Updates & Alerts
ASX AGN:
A$
Home
About
Company Overview
Our Mission
Board & Management
Clinical Advisory Committee
Partnerships
Investors
Share Information
Announcements & Reports
ASX Announcements
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
ASX Announcements
2021
29 Jul 2021
Quarterly Activities/Appendix 4C Cash Flow Report
21 Jul 2021
Grant Secured to Advance Pre-Clinical Studies Of ARG-007
13 Jul 2021
Study Additional Information
12 Jul 2021
Study Shows ARG-007 Does Not Degrade
01 Jul 2021
Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study
30 Jun 2021
Change of Registered Office
16 Jun 2021
Investor Presentation
11 Jun 2021
Argenica Commences Trading on ASX
09 Jun 2021
Becoming a substantial holder
09 Jun 2021
Becoming a substantial holder
09 Jun 2021
Initial Director's Interest Notice x4
09 Jun 2021
Confirmation Statements
09 Jun 2021
Top 20 Holders
09 Jun 2021
Distribution Schedule
09 Jun 2021
Securities Trading Policy
09 Jun 2021
Corporate Governance Statement
09 Jun 2021
Employee Securities Incentive Plan
09 Jun 2021
Interim Report for the period ended 31 December 2020
09 Jun 2021
Annual Report for period from incorporation to 30 June 2020
09 Jun 2021
Constitution
09 Jun 2021
Prospectus
09 Jun 2021
Appendix 1A & Information Form and Checklist
09 Jun 2021
ASX Notice - Admission to Official List
ASX Announcements
Subscribe to our mailing list to stay up to date with Argenica Therapeutics
First Name
*
Last Name
*
Email
*
Home
About
Company Overview
Our Mission
Board & Management
Clinical Advisory Committee
Partnerships
Investors
Share Information
Announcements & Reports
ASX Announcements
Corporate Directory
Corporate Governance
Technology
The Science
Development
Publications
Media
News & Media
Contact
Privacy Policy
Terms & Conditions
ASX Announcements
